Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Identification of 1-Furan-2-yl-3-pyridin-2-yl-propenone, an Anti-inflammatory Agent, and Its Metabolites in Rat Liver Subcellular Fractions

  • Published : 2006.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

1-Furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) has been characterized to have an anti-inflammatory activity through the inhibition of the production of nitric oxide and tumor necrosis $factor-{\alpha}$. In the present studies, the phase 1 metabolism of FPP-3 was investigated in rat liver microsomes and cytosols. When FPP-3 was incubated with rat liver microsomes and cytosols in the presence of NADPH. 2 major peaks were detected on a liquid chromatography/electrospray ionization-mass spectrometry. Two metabolites (i.e., M1 and M2) were characterized as reduced forms on propenone: M1 (1-furan-2-yl-3-pyridin-2-yl-propan-1-one) was the initial metabolite and M2 (1-furan-2-yl-3-pyridin-2-yl-propan-1-ol) was a secondary alcohol believed to be formed from M1.

Keywords

References

  1. Clement, B., Demesmaeker, M., and Linne, S., Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolites: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem. Res. Toxicol., 9, 682-688 (1996) https://doi.org/10.1021/tx9502047
  2. Jahng, Y., Zhao, L. X., Moon, Y.S., Basnet, A., Kim, E. K., Chang, H. W., Ju, H. K., Jeong, T. C., and Lee, E. S., Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities. Bioorg. Med. Chem. Lett., 24, 2559-2562 (2004)
  3. Lee, E. S., Ju, H. K., Moon, T. C., Lee, E., Jahng, Y., Lee, S. H., Son, J. K., Baek, S. H., and Chang, H. W., Inhibition of nitric oxide and tumor necrosis factor-${\alpha}$ production by propenone compound through blockade of nuclear factor-$_{\kappa}B$ activation in cultured murine macrophages. Biol. Pharm. Bull., 27, 617- 620 (2004) https://doi.org/10.1248/bpb.27.617
  4. Lee, E. S., Park, B. C., Paek, S. H., Lee, Y. S., Basnet, A., Jin, D. Q., Choi, H. G., Yong, C. S., and Kim, J. A., Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-ylpropenone with gastric ulcer sparing effect. Biol. Pharm. Bull., 29, 361-364 (2006) https://doi.org/10.1248/bpb.29.361
  5. Lowry, O. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J., Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951)
  6. Maser, E., Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. Biochem. Pharmacol., 49, 421-440 (1995) https://doi.org/10.1016/0006-2952(94)00330-O
  7. Maser, E., 11${\beta}$-Hydroxysteroid dehydrogenase acts as carbonyl reductase in microsomal phase 1 drug metabolism. Exp. Toxic. Pathol., 48, 266-273 (1996)
  8. Maser, E., Friebertshäuser, J., and Völker, B., Purification, characterization and NNK carbonyl reductase activities of 11${\beta}$-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem-Biol. Interact., 143-144, 435-448 (2003)
  9. Mertens, R. and Liese, A., Biotechnological applications of hydrogenase. Curr. Opin. Biotechnol., 15, 343-348 (2004) https://doi.org/10.1016/j.copbio.2004.06.010
  10. Oppermann, U. C. T. and Maser, E., Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenase in xenobiotic phase I reactions. Toxicology, 144, 71-81 (2000) https://doi.org/10.1016/S0300-483X(99)00192-4
  11. Oppermann, U. C. T., Möbus, E., Nagal, G., and Maser, E., Heterogeneity of 11${\beta}$-hydroxysteroid dehydrogenase type 1/ microsomal carbonyl reductase (11${\beta}$-HSD/CR) in guinea pig tissues. Purification of the liver form suggests modification in the cosubstrate binding site. Toxicology, 144, 63-69 (2000) https://doi.org/10.1016/S0300-483X(99)00191-2